DK1531831T3 - Fosinoprilformulering - Google Patents

Fosinoprilformulering

Info

Publication number
DK1531831T3
DK1531831T3 DK03706893T DK03706893T DK1531831T3 DK 1531831 T3 DK1531831 T3 DK 1531831T3 DK 03706893 T DK03706893 T DK 03706893T DK 03706893 T DK03706893 T DK 03706893T DK 1531831 T3 DK1531831 T3 DK 1531831T3
Authority
DK
Denmark
Prior art keywords
fosinopril
formulation
fosinoprilat
ace
prodrug
Prior art date
Application number
DK03706893T
Other languages
English (en)
Inventor
Reynir Eyjolfsson
Original Assignee
Actavis Group Hf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36715398&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1531831(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actavis Group Hf filed Critical Actavis Group Hf
Application granted granted Critical
Publication of DK1531831T3 publication Critical patent/DK1531831T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
DK03706893T 2002-03-19 2003-03-19 Fosinoprilformulering DK1531831T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IS6315A IS1935B (is) 2002-03-19 2002-03-19 Fósínópríl lyfjasamsetning

Publications (1)

Publication Number Publication Date
DK1531831T3 true DK1531831T3 (da) 2006-05-15

Family

ID=36715398

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03706893T DK1531831T3 (da) 2002-03-19 2003-03-19 Fosinoprilformulering

Country Status (13)

Country Link
US (1) US7045511B2 (da)
EP (1) EP1531831B1 (da)
AT (1) ATE314076T1 (da)
AU (1) AU2003208599A1 (da)
DE (1) DE60303041T2 (da)
DK (1) DK1531831T3 (da)
EA (1) EA008171B1 (da)
ES (1) ES2256721T3 (da)
IS (1) IS1935B (da)
NO (1) NO20044390L (da)
PT (1) PT1531831E (da)
UA (1) UA78988C2 (da)
WO (1) WO2003077929A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1635792T3 (pl) * 2003-06-26 2009-08-31 Teva Pharmaceutical Industries Ltd Stabilne kompozycje farmaceutyczne pochodnych kwasu 2-aza-bicyklo[3.3.0]-oktano-3-karboksylowego
US20050095287A1 (en) * 2003-10-29 2005-05-05 Matharu Amol S. Fosinopril composition
GB2411355B (en) * 2004-02-27 2006-02-22 Niche Generics Ltd Pharmaceutical composition
CA2597408A1 (en) * 2005-02-11 2006-08-17 Aventis Pharmaceuticals Inc. Substituted propane phosphinic acid esters
WO2006100602A2 (en) * 2005-03-22 2006-09-28 Aurobindo Pharma Ltd Immediate release stable solid oral dosage forms op fosinopril
US20080015188A1 (en) * 2006-04-19 2008-01-17 Julia Hrakovsky Stable pharmaceutical compositions of 2-aza-bicyclo(3.3.0)-octane-3-carboxylic acid derivatives
GB0612540D0 (en) * 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
ATE406173T1 (de) * 2006-07-10 2008-09-15 Teva Pharma Stabile zubereitung enthaltend eine kombination aus einer feuchtigkeitsempfindlichen aktiven substanz und einer zweiten aktiven substanz und verfahren zur herstellung der zubereitung.
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4337201A (en) * 1980-12-04 1982-06-29 E. R. Squibb & Sons, Inc. Phosphinylalkanoyl substituted prolines
US5006344A (en) * 1989-07-10 1991-04-09 E. R. Squibb & Sons, Inc. Fosinopril tablet formulations
US6521647B2 (en) * 2000-04-04 2003-02-18 Pfizer Inc. Treatment of renal disorders
CA2330904C (en) * 2001-01-11 2006-10-24 Bernard Charles Sherman Fosinopril sodium tablet formulation
KR20040053210A (ko) * 2001-11-02 2004-06-23 화이자 프로덕츠 인크. Ｐｄｅ9 억제제를 사용한 인슐린 저항 증후군 및 2형당뇨병의 치료
ITMI20012366A1 (it) * 2001-11-09 2003-05-09 Farmatron Ltd Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali

Also Published As

Publication number Publication date
PT1531831E (pt) 2006-05-31
DE60303041T2 (de) 2006-08-24
WO2003077929A1 (en) 2003-09-25
US20050256086A1 (en) 2005-11-17
US7045511B2 (en) 2006-05-16
ATE314076T1 (de) 2006-01-15
UA78988C2 (en) 2007-05-10
EP1531831B1 (en) 2005-12-28
EA008171B1 (ru) 2007-04-27
NO20044390L (no) 2004-12-15
IS1935B (is) 2004-06-16
EP1531831A1 (en) 2005-05-25
AU2003208599A1 (en) 2003-09-29
EA200401218A1 (ru) 2005-12-29
DE60303041D1 (de) 2006-02-02
IS6315A (is) 2003-09-20
ES2256721T3 (es) 2006-07-16

Similar Documents

Publication Publication Date Title
CO5590918A2 (es) Formulaciones
CY1109457T1 (el) Παραγωγο aminoαλκοολης ή παραγωγο φωσφονικου οξεος και φαρμακευτικη συνθεση που τα περιεχει
BR0209431A (pt) Novos compostos de 4-anilinoquinolino-3-carboxamidas
MA29854B1 (fr) Nouvelle formulation
MXPA04004464A (es) Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades.
MY138252A (en) Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease
SG10201809390QA (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
NO20081050L (no) Kaspaseinhibitor-prodroger
MA29858B1 (fr) Derives de carbamoylbenzotriazole en tant qu'inhibiteurs de lipases et phospholipases
NO20060847L (no) Substituert 2-aminotetralin til behandling av depresjon
BRPI0518904A2 (pt) formulaÇÕes de nepafenac tàpicas
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
MX2009003926A (es) Composiciones de fenilalquilamino-carbamato.
NO20074544L (no) Inhibering av HER2-losriving med matriksmetalloproteaseantagonister
MA29278B1 (fr) Composition pharmaceutique comprenant un derive de l'indolylmaleimide
TNSN06012A1 (en) Emulsifying systems containing azetidine derivatives
EA200970378A1 (ru) Композиции фенилалкилкарбамата
MXPA04006266A (es) Pirimidotriazinas como inhibidores de fosfatasa.
DK1531831T3 (da) Fosinoprilformulering
BR0112245B1 (pt) Éster de ácido 4-alcóxi-ciclohexano-1-amino-carboxílico
NO20083183L (no) Fast farmasoytisk sammensetning inneholdende irbesartan
WO2008036316A3 (en) Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease
BRPI0411218A (pt) formulações alvejantes fluorescentes estáveis em estocagem
ATE464043T1 (de) Pharmazeutische zusammensetzung enthaltend l- arginin
MXPA06000636A (es) Formulaciones semi-solidas para la administracion oral de taxoides.